Grifols reports Q3 adjusted EBITDA of EUR 462M, up 26.7% in constant currency
Revenue Growth: Grifols reported a 12.4% increase in revenue to EUR 1.793 billion for the third quarter, with adjusted EBITDA rising by 26.7% to EUR 462 million.
CEO's Statement: CEO Nacho Abia expressed pride in the company's performance, highlighting growth momentum, cost control, and ongoing improvement initiatives as key factors in progressing towards their 2024 targets.
Trade with 70% Backtested Accuracy
Analyst Views on GRFS
About GRFS
About the author
Grifols Obtains FDA Approval to Introduce Fesilty in the US by Mid-2026
FDA Approval: Grifols, S.A. has received FDA approval for Fesilty, a human fibrinogen product aimed at treating acute bleeding in patients with congenital fibrinogen deficiency.
Launch Timeline: The product is expected to be launched in the U.S. in the first half of 2026.
Company Statement: Dr. Jörg Schüttrumpf, CEO of Biotest AG, expressed pride in their contribution to enhancing access to life-saving fibrinogen therapies globally.
Stock Performance: Grifols' stock (GRFS) is currently trading at $8.99, reflecting a 0.84 percent increase on the Nasdaq.
Daily Upgrade Report for Validea's Joseph Piotroski Strategy - November 26, 2025
Validea's Upgrades: Today's upgrades for Validea's Book/Market Investor model highlight significant changes in ratings for stocks like Grifols SA, Invesco Ltd, and Molson Coors Beverage Co, reflecting improved fundamentals and valuations.
Grifols SA: The stock rating for Grifols SA increased from 0% to 90%, indicating strong interest based on its financial health and valuation in the biotechnology sector.
Invesco Ltd: Invesco Ltd's rating improved from 0% to 80%, suggesting a positive outlook based on its fundamentals in the investment services industry.
Molson Coors Beverage Co: Molson Coors Beverage Co saw its rating rise from 0% to 90%, demonstrating strong interest due to its financial performance in the alcoholic beverages market.
